Chronic kidney disease after liver, cardiac, lung, heart–lung, and hematopoietic stem cell transplant

Hingorani, Sangeeta

doi:10.1007/s00467-008-0785-2

Cited by 37 publications

(30 citation statements)

References 90 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Renal dysfunction, proteinuria, and hypertension may also be observed in transplant recipients who do not develop TA-TMA [26]. Alternative etiologies, other than TA-TMA, in this patient population include, but are not limited to, exposure to nephrotoxic and prohypertensive medications and infections such as BK virus nephropathy [27,28].…”

Section: Clinical and Histologic Featuresmentioning

confidence: 99%

A new paradigm: Diagnosis and management of HSCT-associated thrombotic microangiopathy as multi-system endothelial injury

Jodele¹,

Laskin²,

Dandoy³

et al. 2015

Blood Reviews

285

340

View full text Add to dashboard Cite

Hematopoietic stem cell transplantation (HSCT)-associated thrombotic microangiopathy (TA-TMA) is now a well-recognized and potentially severe complication of HSCT that carries a high risk of death. In those who survive, TA-TMA may be associated with long-term morbidity and chronic organ injury. Recently, there have been new insights into the incidence, pathophysiology, and management of TA-TMA. Specifically, TA-TMA can manifest as a multi-system disease occurring after various triggers of small vessel endothelial injury, leading to subsequent tissue damage in different organs. While the kidney is most commonly affected, TA-TMA involving organs such as the lung, bowel, heart, and brain is now known to have specific clinical presentations. We now review the most up-to-date research on TA-TMA, focusing on the pathogenesis of endothelial injury, the diagnosis of TA-TMA affecting the kidney and other organs, and new clinical approaches to the management of this complication after HSCT.

show abstract

Section: Clinical and Histologic Featuresmentioning

confidence: 99%

A new paradigm: Diagnosis and management of HSCT-associated thrombotic microangiopathy as multi-system endothelial injury

Jodele¹,

Laskin²,

Dandoy³

et al. 2015

Blood Reviews

285

340

View full text Add to dashboard Cite

show abstract

“…Particular risks factors for HSCT‐related CKD are seldom delved into or followed over long‐term periods. However, several smaller retrospective studies have demonstrated the overall related risks of CKD in pediatric patients . There is a statistically significant association of CKD at 1 year post‐transplant in HSCT patients who developed or maintained AKI at 3 months post‐transplant .…”

Section: Ckd In Hsctmentioning

confidence: 99%

Hematopoietic stem cell transplantation and acute kidney injury in children: A comprehensive review

Raina

Herrera

Krishnappa

et al. 2017

Pediatric Transplantation

View full text Add to dashboard Cite

AKI in the setting of HSCT is commonly investigated among adult patients. In the same way, malignancies requiring treatment with HSCT are not limited to the adult patient population, AKI following HSCT is frequently encountered within pediatric patient populations. However, inadequate information regarding epidemiology and pathophysiology specific to pediatric patients prevents development of appropriate and successful therapeutic strategies for those afflicted. Addressing AKI in the context of sinusoidal obstruction syndrome, chemotherapy, thrombotic microangiopathy and hypertension post chemotherapy, glomerulonephritis, and graft versus host disease provides greater insight into renal impairment associated with these HSCT-related ailments. To obtain a better understanding of AKI among pediatric patients receiving HSCT, we investigated the current literature specifically addressing these areas of concern.

show abstract

“…Chronic kidney disease in long-term survivors after HCT occurs with a reported prevalence from 4% to 89% 50,[82][83][84] depending on the definition used. The National Kidney Foundation Kidney Disease Outcomes Quality Initiative defines chronic kidney disease as a glomerular filtration rate of less than 60 mL/min per 1.73 m 2 for 3 or more months, with or without kidney damage.…”

Section: Long-term Renal Complicationsmentioning

confidence: 99%

How I treat late effects in adults after allogeneic stem cell transplantation

Savani

Griffith

Jagasia

et al. 2011

Blood

105

View full text Add to dashboard Cite

More than 25 000 allogeneic hematopoietic stem cell transplantations (allo-HCTs) are expected to be performed worldwide in 2010, a number that has been increasing yearly. With broadening indications, more options for allo-HCT, and improvement in survival, by 2020 there may be up to half a million long-term survivors after allo-HCT worldwide. These patients have increased risks for various late complications, which can cause morbidity and mortality. Most long-term survivors return to the care of their local hematologists/oncologists or primary care physicians, who may not be familiar with specialized monitoring recommendations for this patient population. The purpose of this article is to describe practical approaches to screening for and managing these late effects, with the goal of reducing preventable morbidity and mortality associated with allo-HCT. (Blood. 2011;117(11):3002-3009) IntroductionSince the first 3 cases of successful allogeneic stem cell transplantation (allo-HCT) in 1968, the number of allo-HCTs performed annually has increased steadily over the past 3 decades. [1][2][3][4] Since 2007, more allo-HCT procedures have been performed using alternative donor stem cell sources, such as volunteer unrelated donors or cord blood than related donors. [3][4][5] With less early mortality and more widespread use of HCT, the number of long-term survivors will continue to grow. Yet, among long-term survivors after allo-HCT, mortality rates are 4-to 9-fold higher than observed in an age-adjusted general population for at least 30 years after HCT, yielding an estimated 30% lower life expectancy compared with someone who has not been transplanted. Among long-term survivors, the most common causes of excess deaths other than recurrent malignancy are chronic graft-versus-host disease (GVHD), infections, second malignancies, respiratory diseases, and cardiovascular disease (CVD). [6][7][8][9][10][11] This article summarizes the medical late effects observed in long-term allo-HCT survivors to frame our recommendations for evaluation and management. Given that there are no randomized trials testing diagnostic and treatment approaches for late effects within the HCT population and only limited published guidelines, we turned to general medicine studies for guidance, augmented by our personal experiences. Therefore, this article offers practical advice and outlines our personal approaches in monitoring longterm survivors after allo-HCT. Management of chronic GVHD is beyond the scope of this article and is often managed in conjunction with transplantation physicians. 12 Second malignanciesAfter allo-HCT, survivors have an increased risk of developing new solid cancers, with the cumulative incidence ranging from 2% to 6% at 10 years after transplantation. [13][14][15][16][17] A study of 28 874 allo-HCT survivors published in 2009 reported that new solid cancers developed at twice the rate expected in the general population, 13 with the risk increasing over time, reaching 3-fold among patients followed for 15 years or more...

show abstract

Chronic kidney disease after liver, cardiac, lung, heart–lung, and hematopoietic stem cell transplant

Cited by 37 publications

References 90 publications

A new paradigm: Diagnosis and management of HSCT-associated thrombotic microangiopathy as multi-system endothelial injury

A new paradigm: Diagnosis and management of HSCT-associated thrombotic microangiopathy as multi-system endothelial injury

Hematopoietic stem cell transplantation and acute kidney injury in children: A comprehensive review

How I treat late effects in adults after allogeneic stem cell transplantation

Contact Info

Product

Resources

About